Upadacitinib treatment regimens, achievement of therapeutic goals and maintenance of response in patients with moderate to severe rheumatoid arthritis in real-world practice (UPHOLD). P20-095
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: ABBVIE SPAIN SLU
- Execution start: 29/09/2021
- End of execution: 30/01/2024
- IP: RAFAEL CALIZ CALIZ